aap

Q1/2016 sales and EBITDA in line with expectations

aap Implantate AG / aap: Q1/2016 sales and EBITDA in line with expectations . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap") achieved in the first quarter of 2016 sales and EBITDA at the group level in line with the guidance. Sales in the reporting period totalled EUR 5.1 million (Q1/2015: EUR 7.1 million) and were thus within the forecast published in February 2016 of EUR 4.5 million to EUR 6.0 million. For the first quarter of 2016 the company posted an EBITDA of EUR -1.9 million (Q1/2015: EUR 0.2 million) that was also within the forecasted corridor of EUR -2.0 million to EUR -1.0 million.

Deteriorated macroeconomic developments in BRICS and SMIT countries negatively influenced our planned sales development in the last year and presented a challenge in the first quarter of 2016 as well. This is characterized by the fact that markets as China, Turkey and Russia did not contribute to the sales in the first quarter. aap has reacted to this and focussed increasingly on established markets and already initiated necessary sales activities in these markets. Overall the company expects the measures to become effective in the second half of 2016.

Sales

In EUR million	Q1/2016	Q1/2015	Change on year
Trauma	2.2	2.6	-16%
Other	0.3	0.3	-3%
Sales continued operation	2.5	2.9	-14%
Sales discontinued operation	2.6	4.2	-39%
Group sales	5.1	7.1	-29%

EBITDA